Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding Div RTS (OP:RHHVF)

484.30 +5.42 (+1.13%)

Streaming Delayed Price Updated: 2:23 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 7 Next >

AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial ↗

October 20, 2021

AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ...

Via Benzinga

Why Are Atea Pharmaceuticals Shares Plunging Today? ↗

October 19, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate...

Via Benzinga

Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting ↗

October 18, 2021

The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with...

Via Benzinga

Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation ↗

October 08, 2021

Roche Holdings AG's (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer's disease. Gantenerumab is...

Via Benzinga

Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection ↗

October 01, 2021

The FDA has granted Emergency Use Authorization (EUA) to Laboratory Corp of America Holdings's (NYSE: LH) combined home collection kit to detect COVID-19 and...

Via Benzinga

BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial ↗

October 01, 2021

BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial...

Via Benzinga

Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail ↗

September 30, 2021

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (...

Via Benzinga

Glaxo - Vir Biotech's COVID Treatment Approved In Japan ↗

September 27, 2021

Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19...

Via Benzinga

Acceleron In Advanced $11B Buyout Talks: Bloomberg ↗

September 27, 2021

Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is...

Via Benzinga

Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients ↗

September 24, 2021

Roche Holding AG (OTC: RHHBY) has highlighted new data for its oral spinal muscular atrophy (SMA) treatment Evrysdi, showing its benefits when given to pre-...

Via Benzinga

WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access ↗

September 24, 2021

The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited...

Via Benzinga

Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know ↗

September 15, 2021

Biogen Inc's (NASDAQ: BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings AG's...

Via Benzinga

Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer ↗

September 14, 2021

Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating...

Via Benzinga

Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition ↗

September 09, 2021

Roche Holdings AG (OTC: RHHBY) has agreed to acquire TIB Molbiol Group for an undisclosed amount. The deal is expected to close in Q4 of 2021. The...

Via Benzinga

MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis ↗

September 08, 2021

MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast...

Via Benzinga

Adaptimmune Stock Moves Higher On Cancer Deal With Genentech ↗

September 07, 2021

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC:...

Via Benzinga

Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy ↗

September 07, 2021

Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD). Spark...

Via Benzinga

See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate ↗

August 31, 2021

AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase...

Via Benzinga

After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US ↗

August 27, 2021

Following a consultation from the FDA, Roche Holdings AG (OTC: RHHBY) has decided to withdraw its immunotherapy, Tecentriq (atezolizumab), to treat a type of...

Via Benzinga

Shape Therapeutics, Roche Form $3B RNA Editing Collaboration ↗

August 24, 2021

Shape Therapeutics Inc announced a multi-target strategic collaboration and license agreement with Roche Holding AG (OTC: RHHBY) for RNA editing technology....

Via Benzinga

UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail ↗

August 20, 2021

The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent...

Via Benzinga

Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage ↗

August 17, 2021

Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after...

Via Benzinga

AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer ↗

August 09, 2021

AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3...

Via Benzinga

Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients ↗

August 09, 2021

Genentech, a member of Roche Holdings AG (OTC: RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people with previously...

Via Benzinga

Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg ↗

August 04, 2021

SoftBank Group Corp (OTC: SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC: RHHBF), making it one of the largest investors of the Roche,...

Via Benzinga

Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer ↗

August 03, 2021

The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) Tecentriq (atezolizumab), as adjuvant treatment for...

Via Benzinga

FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis ↗

August 02, 2021

Following the June update that

Via Benzinga

Roche's Faricimab US Application For Ocular Diseases Under Priority Review ↗

July 29, 2021

The FDA has accepted Roche Holding AG's (OTC: RHHBY) Biologics License Application seeking approval for faricimab in neovascular of wet age-related macular...

Via Benzinga

Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings ↗

July 27, 2021

Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49...

Via Benzinga

Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters ↗

July 22, 2021

Roche Holding AG (OTC: RHHBY) is reportedly talking to the FDA about its Alzheimer’s disease drug candidate, gantenerumab. CEO Severin Schwan declined...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Roche Holding Div RTS (OP:RHHVF)

All News about Roche Holding Div RTS

Starting at $3.75/week.

Subscribe Today